1
|
Berriri S, Zribi K, Gloulou O, Mokni Y, Safta F. Development, optimization and validation of an analytical method for the determination of voriconazole in plasma by high-performance liquid chromatography-ultraviolet detection: Application for comprehensive study. ANNALES PHARMACEUTIQUES FRANÇAISES 2024; 82:886-897. [PMID: 38729517 DOI: 10.1016/j.pharma.2024.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2024] [Revised: 05/02/2024] [Accepted: 05/04/2024] [Indexed: 05/12/2024]
Abstract
OBJECTIVES Voriconazole is a widely used antifungal agent in clinical settings. However, its use has been associated with neurological side effects in some patients. For this reason, it is crucial to monitor its plasma levels to ensure that they are within the therapeutic range. Thus, in this study, we aimed to develop a simple, fast, and efficient method for the determination of voriconazole in plasma using reversed-phase HPLC-UV. We also aimed to validate the method for its application to routine analysis of immunocompromised patients. MATERIAL AND METHODS Plasma samples from immunocompromised patients were subjected to deproteinization with acetonitrile followed by centrifugation. Chromatographic separation was carried out on a C18 column with UV detection at 254nm in isocratic mode. The concentrations were calculated by comparing peak areas to those of the internal standard, ketoconazole. The method was validated using the accuracy profile, which uses a calibration curve established for the therapeutic range of 1 to 5.5μg/mL. RESULTS The developed method was proved to be rapid by giving a short analysis time for voriconazole at around 5.5min. Additionally, no interference with the biological matrix was detected. The obtained recoveries were higher than 90%. The accuracy profile showed that the method was accurate and precise for the determination of voriconazole in plasma. CONCLUSION The developed method was proved to be simple, efficient, that requires minimal sample preparation. Thus, it can be routinely applied for the therapeutic monitoring of voriconazole.
Collapse
Affiliation(s)
- Sarra Berriri
- Laboratory for the Chemical, Galenic and Pharmacological Development of Medicines LR12ES09, Faculty of pharmacy Monastir, avenue Ibn Sina, 5000 Monastir, Tunisia.
| | - Kaouther Zribi
- Laboratory for the Chemical, Galenic and Pharmacological Development of Medicines LR12ES09, Faculty of pharmacy Monastir, avenue Ibn Sina, 5000 Monastir, Tunisia
| | - Olfa Gloulou
- Pharmacy Department, Farhat Hached University Hospital, Sousse, Tunisia
| | - Yassine Mokni
- Laboratory for the Chemical, Galenic and Pharmacological Development of Medicines LR12ES09, Faculty of pharmacy Monastir, avenue Ibn Sina, 5000 Monastir, Tunisia
| | - Fathi Safta
- Laboratory for the Chemical, Galenic and Pharmacological Development of Medicines LR12ES09, Faculty of pharmacy Monastir, avenue Ibn Sina, 5000 Monastir, Tunisia
| |
Collapse
|
2
|
Zapata JD, Cáceres DH, Cano LE, de Bedout C, Granada SD, Naranjo TW. Standardization and validation of a high-efficiency liquid chromatography with a diode-array detector (HPLC-DAD) for voriconazole blood level determination. BIOMEDICA : REVISTA DEL INSTITUTO NACIONAL DE SALUD 2024; 44:113-118. [PMID: 38648347 PMCID: PMC11223762 DOI: 10.7705/biomedica.6959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Accepted: 01/22/2024] [Indexed: 04/25/2024]
Abstract
INTRODUCTION A specialized service for antifungal blood level determination is not available in Colombia. This service is essential for the proper follow-up of antifungal therapies. OBJECTIVE To standardize and validate a simple, sensitive, and specific protocol based on high-performance liquid chromatography with a diode array detector for voriconazole blood level quantification. MATERIALS AND METHODS We used an Agilent HPLC™ series-1200 equipment with a UVdiode array detector with an analytical column Eclipse XDB-C18 and pre-column Eclipse- XDB-C18 (Agilent). We used voriconazole as the primary control and posaconazole as an internal control. We performed the validation following the Food and Drug Administration (FDA) recommendations. RESULTS The best chromatographic conditions were: Column temperature of 25°C, UV variable wavelength detection at 256 nm for voriconazole and 261 nm for posaconazole (internal standard); 50 μl of injection volume, 0,8 ml/min volume flow, 10 minutes of run time, and mobile phase of acetonitrile:water (60:40). Finally, retention times were 3.13 for voriconazole and 5.16 minutes for posaconazole. Quantification range varied from 0.125 μg/ml to 16 μg/ml. CONCLUSION The selectivity and chromatographic purity of the obtained signal, the detection limits, and the standardized quantification make this method an excellent tool for the therapeutic monitoring of patients treated with voriconazole.
Collapse
Affiliation(s)
- Juan D. Zapata
- Unidad de Micología Médica y Experimental, Corporación para Investigaciones Biológicas, Medellín, ColombiaCorporación para Investiga. BiológicasUnidad de Micología Médica y ExperimentalCorporación para Investigaciones BiológicasMedellínColombia
- Unidad de Investigación Clínica, Corporación para Investigaciones Biológicas, Medellín, ColombiaCorporación para Investiga. BiológicasUnidad de Investigación ClínicaCorporación para Investigaciones BiológicasMedellínColombia
- These authors contributed equally on this project.
| | - Diego H. Cáceres
- Unidad de Micología Médica y Experimental, Corporación para Investigaciones Biológicas, Medellín, ColombiaCorporación para Investiga. BiológicasUnidad de Micología Médica y ExperimentalCorporación para Investigaciones BiológicasMedellínColombia
- These authors contributed equally on this project.
| | - Luz E. Cano
- Unidad de Micología Médica y Experimental, Corporación para Investigaciones Biológicas, Medellín, ColombiaCorporación para Investiga. BiológicasUnidad de Micología Médica y ExperimentalCorporación para Investigaciones BiológicasMedellínColombia
- Escuela de Microbiología, Universidad de Antioquia, Medellín, ColombiaUniversidad de AntioquiaEscuela de MicrobiologíaUniversidad de AntioquiaMedellínColombia
| | - Catalina de Bedout
- Unidad de Micología Médica y Experimental, Corporación para Investigaciones Biológicas, Medellín, ColombiaCorporación para Investiga. BiológicasUnidad de Micología Médica y ExperimentalCorporación para Investigaciones BiológicasMedellínColombia
| | - Sinar D. Granada
- Unidad de Fitosanidad y Control Biológico, Corporación para Investigaciones Biológicas, Medellín, ColombiaCorporación para Investiga. BiológicasUnidad de Fitosanidad y Control BiológicoCorporación para Investigaciones BiológicasMedellínColombia
| | - Tonny W. Naranjo
- Unidad de Micología Médica y Experimental, Corporación para Investigaciones Biológicas, Medellín, ColombiaCorporación para Investiga. BiológicasUnidad de Micología Médica y ExperimentalCorporación para Investigaciones BiológicasMedellínColombia
- Escuela de Ciencias de la Salud, Universidad Pontificia Bolivariana, Medellín, ColombiaPontificia Universidad BolivarianaEscuela de Ciencias de la SaludUniversidad Pontificia BolivarianaMedellínColombia
- Unidad de Biología de Sistemas, Escuela de Ciencias de la Salud, Universidad Pontificia Bolivariana, Medellín, ColombiaPontificia Universidad BolivarianaUnidad de Biología de SistemasEscuela de Ciencias de la SaludUniversidad Pontificia BolivarianaMedellínColombia
| |
Collapse
|
3
|
Chanduluru HK, Sugumaran A. Assessment of greenness for the determination of voriconazole in reported analytical methods. RSC Adv 2022; 12:6683-6703. [PMID: 35424637 PMCID: PMC8982219 DOI: 10.1039/d1ra08858k] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Accepted: 02/04/2022] [Indexed: 12/30/2022] Open
Abstract
Analytical research with adverse environmental impact has caused a severe rise in concern about the ecological consequences of its strategies, most notably the use and emission of harmful solvents/reagents into the atmosphere. Nowadays, industries are searching for the best reproducible methods. Voriconazole is a second-generation azole derivative used effectively in the treatment of Candida and Aspergillus species infections and oropharyngeal candidiasis in AIDS patients. Recently it has become the drug of choice in treating mucormycosis in several countries, which raises the need for production in large quantities. The present review deals with various recent important analytical techniques used to estimate voriconazole and its combination in pharmaceutical formulations and biological fluids. The methods show their own unique way of analyzing voriconazole in different matrices with excellent linearity, detection, and quantification limits. Additionally, this article deals with methods and solvents analyzed for their impact on the environment. This is followed by estimating the degree of greenness of the methods using various available assessment tools like analytical eco-scale, national environmental method index, green analytical procedure index, and AGREE metrics to confirm the environmental impact. The scores obtained with the evaluation tools depict the quantum of greenness for the reported methods and provide an ideal approach adopted for VOR estimation. Very few methods are eco-friendly, which shows that there is a need for the budding analyst to develop methods based on green analytical principles to protect the environment.
Collapse
Affiliation(s)
- Hemanth Kumar Chanduluru
- SRM College of Pharmacy, SRM Institute of Science and Technology Kattankulathur 603203 India +91 7904062599
| | - Abimanyu Sugumaran
- SRM College of Pharmacy, SRM Institute of Science and Technology Kattankulathur 603203 India +91 7904062599
| |
Collapse
|
4
|
Rangam NV, Sudagar AJ, Ruszczak A, Borowicz P, Tóth J, Kövér L, Michałowska D, Roszko MŁ, Noworyta KR, Lesiak B. Valorizing the Unexplored Filtration Waste of Brewing Industry for Green Silver Nanocomposite Synthesis. NANOMATERIALS 2022; 12:nano12030442. [PMID: 35159787 PMCID: PMC8839514 DOI: 10.3390/nano12030442] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Revised: 01/25/2022] [Accepted: 01/26/2022] [Indexed: 02/04/2023]
Abstract
The brewing industry generates a substantial amount of by-products rich in polyphenols, carbohydrates, sugars, sulfates, nitrogen compounds, organic carbon, and several elements, including chlorine, magnesium, and phosphorus. Although limited quantities of these by-products are used in fertilizers and composts, a large amount is discarded as waste. Therefore, it is crucial to identify different ways of valorizing the by-products. Research regarding the valorization of the brewery by-products is still in its nascent stage; therefore, it still has high potential. Herein, we report the valorization of the brewery by-product from the filtration stage of the brewing process (BW9) to synthesize silver nanocomposites as this waste has remained largely unexplored. The BW9 nanocomposites have been compared to those obtained from the brewery product B. The chemical composition analysis of BW9 and B revealed several organic moieties capable of reducing metal salts and capping the formed nanoparticles. Therefore, the brewery waste from stage 9 was valorized as a precursor and added to silver-based precursor at various temperatures (25, 50, and 80 °C) and for various time periods (10, 30, and 120 min) to synthesize silver nanocomposites. The nanocomposites obtained using BW9 were compared to those obtained using the main product of the brewing industry, beer (B). Synthesized nanocomposites composed of AgCl as a major phase and silver metal (Agmet) was incorporated in minor quantities. In addition, Ag3PO4 was also found in B nanocomposites in minor quantities (up to 34 wt.%). The surface morphology depicted globular nanoparticles with layered structures. Small ball-like aggregates on the layer representative of Ag3PO4 were observed in B nanocomposites. The surface of nanocomposites was capped with organic content and functional groups present in the brewery products. The nanocomposites demonstrated high antibacterial activity against Escherichia coli (E. coli), with BW9 nanocomposites exhibiting a higher activity than B nanocomposites.
Collapse
Affiliation(s)
- Neha Venkatesh Rangam
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland; (A.R.); (P.B.); (K.R.N.); (B.L.)
- Correspondence: or (N.V.R.); or (A.J.S.)
| | - Alcina Johnson Sudagar
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland; (A.R.); (P.B.); (K.R.N.); (B.L.)
- Correspondence: or (N.V.R.); or (A.J.S.)
| | - Artur Ruszczak
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland; (A.R.); (P.B.); (K.R.N.); (B.L.)
| | - Paweł Borowicz
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland; (A.R.); (P.B.); (K.R.N.); (B.L.)
| | - József Tóth
- Institute for Nuclear Research, BemTér 18/c, H-4026 Debrecen, Hungary; (J.T.); (L.K.)
| | - László Kövér
- Institute for Nuclear Research, BemTér 18/c, H-4026 Debrecen, Hungary; (J.T.); (L.K.)
| | - Dorota Michałowska
- Institute of Agriculture and Food Biotechnology—State Research Institute, ul. Rakowiecka 36, 02-532 Warsaw, Poland; (D.M.); (M.Ł.R.)
| | - Marek Łukasz Roszko
- Institute of Agriculture and Food Biotechnology—State Research Institute, ul. Rakowiecka 36, 02-532 Warsaw, Poland; (D.M.); (M.Ł.R.)
| | - Krzysztof Robert Noworyta
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland; (A.R.); (P.B.); (K.R.N.); (B.L.)
| | - Beata Lesiak
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland; (A.R.); (P.B.); (K.R.N.); (B.L.)
| |
Collapse
|
5
|
Sudagar AJ, Rangam NV, Ruszczak A, Borowicz P, Tóth J, Kövér L, Michałowska D, Roszko MŁ, Noworyta KR, Lesiak B. Valorization of Brewery Wastes for the Synthesis of Silver Nanocomposites Containing Orthophosphate. NANOMATERIALS (BASEL, SWITZERLAND) 2021; 11:2659. [PMID: 34685100 PMCID: PMC8539218 DOI: 10.3390/nano11102659] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/05/2021] [Revised: 10/03/2021] [Accepted: 10/04/2021] [Indexed: 11/16/2022]
Abstract
Brewery wastes from stage 5 (Wort precipitate: BW5) and stage 7 (Brewer's spent yeast: BW7) were valorized for the synthesis of silver phosphate nanocomposites. Nanoparticles were synthesized by converting silver salt in the presence of brewery wastes at different temperatures (25, 50, and 80 °C) and times (10, 30, and 120 min). Unexpectedly, BW7 yielded Ag3PO4 nanoparticles with minor contents of AgCl and Ag metal (Agmet). Contrastingly, BW5 produced AgCl nanoparticles with minor amounts of Ag3PO4 and Agmet. Nanocomposites with different component ratios were obtained by simply varying the synthesis temperature and time. The morphology of the nanocomposites contained ball-like structures representative of Ag3PO4 and stacked layers and fused particles representing AgCl and Agmet. The capping on the nanoparticles contained organic groups from the brewery by-products, and the surface overlayer had a rich chemical composition. The organic overlayers on BW7 nanocomposites were thinner than those on BW5 nanocomposites. Notably, the nanocomposites exhibited high antibacterial activity against Escherichia coli ATCC 25922. The antibacterial activity was higher for BW7 nanocomposites due to a larger silver phosphate content in the composition and a thin organic overlayer. The growth of Agmet in the structure adversely affected the antimicrobial property of the nanocomposites.
Collapse
Affiliation(s)
- Alcina Johnson Sudagar
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland
| | - Neha Venkatesh Rangam
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland
| | - Artur Ruszczak
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland
| | - Paweł Borowicz
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland
| | - József Tóth
- Institute for Nuclear Research, BemTér 18/c, H-4026 Debrecen, Hungary
| | - László Kövér
- Institute for Nuclear Research, BemTér 18/c, H-4026 Debrecen, Hungary
| | - Dorota Michałowska
- Institute of Agriculture and Food Biotechnology-State Research Institute, ul. Rakowiecka 36, 02-532 Warsaw, Poland
| | - Marek Ł Roszko
- Institute of Agriculture and Food Biotechnology-State Research Institute, ul. Rakowiecka 36, 02-532 Warsaw, Poland
| | - Krzysztof R Noworyta
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland
| | - Beata Lesiak
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland
| |
Collapse
|
6
|
A New Application of MALDI Biotyper for a Potential Use in Therapeutic Drug Monitoring of Voriconazole. Antimicrob Agents Chemother 2021; 65:e0245820. [PMID: 33972255 DOI: 10.1128/aac.02458-20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
We present a proof-of-concept study on the use of MALDI Biotyper to detect and monitor the levels of voriconazole in human serum. A simple extraction-concentration method and a MALDI Biotyper protocol were developed, and a parent ion of voriconazole (1 H+) could be detected and quantified with good reproducibility. Our results point to a new application of MALDI Biotyper for therapeutic drug monitoring.
Collapse
|
7
|
Blanco-Dorado S, Belles Medall MD, Pascual-Marmaneu O, Campos-Toimil M, Otero-Espinar FJ, Rodríguez-Riego R, Rodríguez-Jato T, Zarra-Ferro I, Lamas MJ, Fernández-Ferreiro A. Therapeutic drug monitoring of voriconazole: validation of a high performance liquid chromatography method and comparison with an ARK immunoassay. Eur J Hosp Pharm 2021. [DOI: 10.1136/ejhpharm-2019-002155] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
8
|
Blanco-Dorado S, Maroñas O, Latorre-Pellicer A, Rodríguez Jato MT, López-Vizcaíno A, Gómez Márquez A, Bardán García B, Belles Medall D, Barbeito Castiñeiras G, Pérez Del Molino Bernal ML, Campos-Toimil M, Otero Espinar F, Blanco Hortas A, Durán Piñeiro G, Zarra Ferro I, Carracedo Á, Lamas MJ, Fernández-Ferreiro A. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study. Pharmacotherapy 2020; 40:17-25. [PMID: 31782536 DOI: 10.1002/phar.2351] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
BACKGROUND Voriconazole, a first-line agent for the treatment of invasive fungal infections, is mainly metabolized by cytochrome P450 (CYP) 2C19. A significant portion of patients fail to achieve therapeutic voriconazole trough concentrations, with a consequently increased risk of therapeutic failure. OBJECTIVE To show the association between subtherapeutic voriconazole concentrations and factors affecting voriconazole pharmacokinetics: CYP2C19 genotype and drug-drug interactions. METHODS Adults receiving voriconazole for antifungal treatment or prophylaxis were included in a multicenter prospective study conducted in Spain. The prevalence of subtherapeutic voriconazole troughs was analyzed in the rapid metabolizer and ultra-rapid metabolizer patients (RMs and UMs, respectively), and compared with the rest of the patients. The relationship between voriconazole concentration, CYP2C19 phenotype, adverse events (AEs), and drug-drug interactions was also assessed. RESULTS In this study 78 patients were included with a wide variability in voriconazole plasma levels with only 44.8% of patients attaining trough concentrations within the therapeutic range of 1 and 5.5 µg/ml. The allele frequency of *17 variant was found to be 29.5%. Compared with patients with other phenotypes, RMs and UMs had a lower voriconazole plasma concentration (RM/UM: 1.85 ± 0.24 µg/ml vs other phenotypes: 2.36 ± 0.26 µg/ml). Adverse events were more common in patients with higher voriconazole concentrations (p<0.05). No association between voriconazole trough concentration and other factors (age, weight, route of administration, and concomitant administration of enzyme inducer, enzyme inhibitor, glucocorticoids, or proton pump inhibitors) was found. CONCLUSION These results suggest the potential clinical utility of using CYP2C19 genotype-guided voriconazole dosing to achieve concentrations in the therapeutic range in the early course of therapy. Larger studies are needed to confirm the impact of pharmacogenetics on voriconazole pharmacokinetics.
Collapse
Affiliation(s)
- Sara Blanco-Dorado
- Pharmacy Department, University Clinical Hospital Santiago de Compostela (CHUS), Santiago de Compostela, Spain.,Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital, Santiago de Compostela, Spain.,Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Olalla Maroñas
- Genomic Medicine Group, Centro Nacional de Genotipado (CEGEN-PRB3), CIBERER, CIMUS, University of Santiago de Compostela (USC), Santiago de Compostela, Spain.,Galician Foundation of Genomic Medicine, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, Santiago de Compostela, Spain
| | - Ana Latorre-Pellicer
- Genomic Medicine Group, Centro Nacional de Genotipado (CEGEN-PRB3), CIBERER, CIMUS, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - María Teresa Rodríguez Jato
- Pharmacy Department, University Clinical Hospital Santiago de Compostela (CHUS), Santiago de Compostela, Spain
| | - Ana López-Vizcaíno
- Pharmacy Department, University Hospital Lucus Augusti (HULA), Lugo, Spain
| | | | | | | | - Gema Barbeito Castiñeiras
- Microbiology Department, University Clinical Hospital Santiago de Compostela (CHUS), Santiago de Compostela, Spain
| | | | - Manuel Campos-Toimil
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Francisco Otero Espinar
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Andrés Blanco Hortas
- Epidemiology Unit, Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), University Hospital Lucus Augusti (HULA), Lugo, Spain
| | - Goretti Durán Piñeiro
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital, Santiago de Compostela, Spain
| | - Irene Zarra Ferro
- Pharmacy Department, University Clinical Hospital Santiago de Compostela (CHUS), Santiago de Compostela, Spain.,Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital, Santiago de Compostela, Spain
| | - Ángel Carracedo
- Genomic Medicine Group, Centro Nacional de Genotipado (CEGEN-PRB3), CIBERER, CIMUS, University of Santiago de Compostela (USC), Santiago de Compostela, Spain.,Galician Foundation of Genomic Medicine, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, Santiago de Compostela, Spain
| | - María Jesús Lamas
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital, Santiago de Compostela, Spain
| | - Anxo Fernández-Ferreiro
- Pharmacy Department, University Clinical Hospital Santiago de Compostela (CHUS), Santiago de Compostela, Spain.,Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital, Santiago de Compostela, Spain.,Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| |
Collapse
|
9
|
Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases. Eur J Clin Pharmacol 2020; 76:833-842. [PMID: 32157329 DOI: 10.1007/s00228-020-02841-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Accepted: 01/29/2020] [Indexed: 11/30/2022]
Abstract
PURPOSE To evaluate the influence of three proton pump inhibitors (PPIs) on plasma voriconazole (VOR) concentrations and characterize potential drug-drug interactions (DDIs) between VOR and three PPIs (omeprazole, lansoprazole, and pantoprazole) in Chinese patients with malignant hematological diseases. METHODS A simple and reliable 2D-HPLC with internal quality control method was used to ensure accurate concentration measurements. A total of 194 patients in this retrospective study were divided into control (N = 59), omeprazole (OME, N = 57), lansoprazole (LAN, N = 26), and pantoprazole (PAN, N = 52) groups for comparison of plasma VOR trough concentrations. To further validate our retrospective analysis of clinical data, we used molecular docking simulation to analyze the binding affinity of PPIs to the cytochrome P450 2C19 (CYP2C19) and cytochrome P450 3A4 (CYP3A4) enzymes that are integral to the metabolism of PPIs and VOR. RESULTS Our findings indicated that VOR trough concentrations were significantly higher in patient on PPIs compared with those who were not (P = 0.012). Patients on LAN (P < 0.01) or OME (P < 0.05) had significantly elevated VOR concentrations compared with the control group, whereas those on PAN did not. Although VOR trough concentrations were not significantly elevated with PAN, more patients in the PAN group reached therapeutic VOR concentrations than in any other group. CONCLUSION In conclusion, our retrospective data analysis and molecular docking simulations results indicate that LAN and OME interact with VOR via CYP2C19 and CYP3A4 to increase VOR plasma concentrations. This study helps with selection of PPIs in Chinese patients with malignant hematological cancer administered VOR.
Collapse
Affiliation(s)
- Qi Huang
- Department of Pharmacy, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.,Institute of Hospital Pharmacy, Central South University, Changsha, 410008, China.,National Clinical Research Center for Geriatric Disorders, Institute for Rational and Safe Medication Practices, Xiangya Hospital, Central South University, Changsha, 410008, China
| | - Qiong Liu
- Department of Radiation Oncology, Xiangya Hospital, Central South University, Changsha, 410008, China
| | - Tao Yin
- Department of Pharmacy, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.,Institute of Hospital Pharmacy, Central South University, Changsha, 410008, China.,National Clinical Research Center for Geriatric Disorders, Institute for Rational and Safe Medication Practices, Xiangya Hospital, Central South University, Changsha, 410008, China
| | - Lin Hu
- Department of Pharmacy, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.,Institute of Hospital Pharmacy, Central South University, Changsha, 410008, China.,National Clinical Research Center for Geriatric Disorders, Institute for Rational and Safe Medication Practices, Xiangya Hospital, Central South University, Changsha, 410008, China
| | - Hanjun Ding
- School of Pharmacy, Hubei University of Science and Technology, Xianning, 437100, China
| | - Shao Liu
- Department of Pharmacy, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China. .,Institute of Hospital Pharmacy, Central South University, Changsha, 410008, China. .,National Clinical Research Center for Geriatric Disorders, Institute for Rational and Safe Medication Practices, Xiangya Hospital, Central South University, Changsha, 410008, China.
| | - Yueping Jiang
- Department of Pharmacy, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China. .,Institute of Hospital Pharmacy, Central South University, Changsha, 410008, China. .,National Clinical Research Center for Geriatric Disorders, Institute for Rational and Safe Medication Practices, Xiangya Hospital, Central South University, Changsha, 410008, China.
| |
Collapse
|
10
|
Simultaneous quantification of systemic azoles and their major metabolites in human serum by HPLC/PDA: role of azole metabolic rate. Diagn Microbiol Infect Dis 2018; 92:78-83. [DOI: 10.1016/j.diagmicrobio.2018.04.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Revised: 02/07/2018] [Accepted: 04/06/2018] [Indexed: 01/12/2023]
|
11
|
Lei M, Yao H, Dong Y, Wang M, Wang Z, Cheng X. Development and validation of an LC-MS/MS method for simultaneous quantification of voriconazole and its main metabolite voriconazole N-oxide in human plasma and its clinical application. J LIQ CHROMATOGR R T 2017. [DOI: 10.1080/10826076.2017.1402187] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Meng Lei
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
| | - Hongping Yao
- Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
| | - Yalin Dong
- Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
| | - Maoyi Wang
- Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
| | - Zheng Wang
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
| | - Xiaoliang Cheng
- Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
| |
Collapse
|
12
|
Spósito PÁ, Mazzeti AL, de Oliveira Faria C, Urbina JA, Pound-Lana G, Bahia MT, Mosqueira VF. Ravuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity. Int J Nanomedicine 2017; 12:3785-3799. [PMID: 28553114 PMCID: PMC5439725 DOI: 10.2147/ijn.s133708] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Self-emulsifying drug delivery systems (SEDDSs) are lipid-based anhydrous formulations composed of an isotropic mixture of oil, surfactant, and cosurfactants usually presented in gelatin capsules. Ravuconazole (Biopharmaceutics Classification System [BCS] Class II) is a poorly water-soluble drug, and a SEDDS type IIIA was designed to deliver it in a predissolved state, improving dissolution in gastrointestinal fluids. After emulsification, the droplets had mean hydrodynamic diameters <250 nm, zeta potential values in the range of −45 mV to −57 mV, and showed no signs of ravuconazole precipitation. Asymmetric flow field-flow fractionation with dynamic and multiangle laser light scattering was used to characterize these formulations in terms of size distribution and homogeneity. The fractograms obtained at 37°C showed a polydisperse profile for all blank and ravuconazole–SEDDS formulations but no large aggregates. SEDDS increased ravuconazole in vitro dissolution extent and rate (20%) compared to free drug (3%) in 6 h. The in vivo toxicity of blank SEDDS comprising Labrasol® surfactant in different concentrations and preliminary safety tests in repeated-dose oral administration (20 days) showed a dose-dependent Labrasol toxicity in healthy mice. Ravuconazole–SEDDS at low surfactant content (10%, v/v) in Trypanosoma cruzi-infected mice was safe during the 20-day treatment. The anti-T. cruzi activity of free ravuconazole, ravuconazole–SEDDS and each excipient were evaluated in vitro at equivalent ravuconazole concentrations needed to inhibit 50% or 90% (IC50 and IC90), respectively of the intracellular amastigote form of the parasite in a cardiomyocyte cell line. The results showed a clear improvement of the ravuconazole anti-T. cruzi activity when associated with SEDDS. Based on our results, the repurposing of ravuconazole in SEDDS dosage form is a strategy that deserves further in vivo investigation in preclinical studies for the treatment of human T. cruzi infections.
Collapse
Affiliation(s)
- Pollyanna Álvaro Spósito
- Laboratory of Pharmaceutics and Nanotechnology Research, Pharmacy Department, School of Pharmacy, Universidade Federal de Ouro Preto, Minas Gerais, Brazil
| | - Ana Lia Mazzeti
- Laboratory of Pharmaceutics and Nanotechnology Research, Pharmacy Department, School of Pharmacy, Universidade Federal de Ouro Preto, Minas Gerais, Brazil.,Parasite Diseases Research Laboratory, NUPEB, Medical School, Universidade Federal de Ouro Preto, MG, Brazil
| | - Caroline de Oliveira Faria
- Laboratory of Pharmaceutics and Nanotechnology Research, Pharmacy Department, School of Pharmacy, Universidade Federal de Ouro Preto, Minas Gerais, Brazil
| | - Julio A Urbina
- Venezuelan Institute for Scientific Research, Apartado, Caracas, Venezuela
| | - Gwenaelle Pound-Lana
- Laboratory of Pharmaceutics and Nanotechnology Research, Pharmacy Department, School of Pharmacy, Universidade Federal de Ouro Preto, Minas Gerais, Brazil
| | - Maria Terezinha Bahia
- Parasite Diseases Research Laboratory, NUPEB, Medical School, Universidade Federal de Ouro Preto, MG, Brazil
| | - Vanessa Furtado Mosqueira
- Laboratory of Pharmaceutics and Nanotechnology Research, Pharmacy Department, School of Pharmacy, Universidade Federal de Ouro Preto, Minas Gerais, Brazil
| |
Collapse
|
13
|
Therapeutic Drug Monitoring of Voriconazole: Comparison of Bioassay with High-Performance Liquid Chromatography. Jundishapur J Microbiol 2017. [DOI: 10.5812/jjm.45645] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
|
14
|
Cendejas-Bueno E, Borobia AM, Gomez-Lopez A, Escosa-García L, Río-García M, Plaza D, García-Rodriguez J, Carcas-Sansuán A. Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible Aspergillus fumigatus: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms. Int J Antimicrob Agents 2016; 47:410-1. [PMID: 27056297 DOI: 10.1016/j.ijantimicag.2016.02.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Revised: 02/10/2016] [Accepted: 02/14/2016] [Indexed: 10/22/2022]
Affiliation(s)
| | - Alberto M Borobia
- Clinical Pharmacology Department, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain
| | - Alicia Gomez-Lopez
- Mycology Department, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
| | - Luis Escosa-García
- Paediatric Infectious Diseases Unit, Hospital Universitario La Paz, Madrid, Spain
| | - Miguel Río-García
- Pediatric Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain
| | - Diego Plaza
- Paediatric Hematology-Oncology Department, Hospital Universitario La Paz, Madrid, Spain
| | | | | |
Collapse
|
15
|
Forastiero A, Bernal-Martínez L, Mellado E, Cendejas E, Gomez-Lopez A. In vivo efficacy of voriconazole and posaconazole therapy in a novel invertebrate model of Aspergillus fumigatus infection. Int J Antimicrob Agents 2015; 46:511-7. [PMID: 26358971 DOI: 10.1016/j.ijantimicag.2015.07.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2015] [Revised: 06/05/2015] [Accepted: 07/07/2015] [Indexed: 02/05/2023]
Abstract
The emergence of azole resistance in Aspergillus fumigatus is a clinically important issue in the management of invasive aspergillosis as it could limit therapeutic options. Accurate measurement of in vitro antifungal activity in terms of minimum inhibitory concentration (MIC) is considered of clinical relevance and often gives useful therapeutic information for physicians. However, the lack of in vitro-in vivo correlation is frequent and the observed in vitro phenotype does not always correlate with the in vivo response. In this regard, a wild-type strain and five A. fumigatus cyp51A mutated strains showing different azole susceptibility profiles were used to investigate whether the greater wax moth (Galleria mellonella) is an alternative model to assess the in vivo efficacy of voriconazole and posaconazole. Administration of both azoles improved the survival of larvae infected with susceptible strains. However, those larvae infected with resistant strains did not respond to treatment. The phenotype observed in vitro was found to correlate with the efficacy observed in vivo. Moreover, using this in vivo model, the pharmacodynamic target predicting therapeutic success (AUC(0-24)/MIC) was in the same range as previously described, allowing the use of the G. mellonella model to predict the azole susceptibility profile of A. fumigatus strains.
Collapse
Affiliation(s)
- A Forastiero
- Mycology Reference Laboratory, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km 2, Majadahonda, 28220 Madrid, Spain
| | - L Bernal-Martínez
- Mycology Reference Laboratory, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km 2, Majadahonda, 28220 Madrid, Spain
| | - E Mellado
- Mycology Reference Laboratory, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km 2, Majadahonda, 28220 Madrid, Spain
| | - E Cendejas
- Mycology Reference Laboratory, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km 2, Majadahonda, 28220 Madrid, Spain
| | - A Gomez-Lopez
- Mycology Reference Laboratory, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km 2, Majadahonda, 28220 Madrid, Spain.
| |
Collapse
|
16
|
Wang Z, Huang CK, Sun W, Xiao C, Wang ZS. UPLC-MS/MS determination of voriconazole in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr 2014; 29:188-93. [PMID: 24925071 DOI: 10.1002/bmc.3257] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2013] [Revised: 04/07/2014] [Accepted: 04/26/2014] [Indexed: 11/06/2022]
Affiliation(s)
- Zhe Wang
- Department of Pharmacy; The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University; Wenzhou 325027 China
| | - Cheng-ke Huang
- Department of Pharmacy; The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University; Wenzhou 325027 China
| | - Wei Sun
- Department of Pharmacy; The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University; Wenzhou 325027 China
| | - Cui Xiao
- Department of Pharmacy; The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University; Wenzhou 325027 China
| | - Zeng-shou Wang
- Department of Pharmacy; The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University; Wenzhou 325027 China
| |
Collapse
|
17
|
Determination of voriconazole serum concentration by bioassay, a valid method for therapeutic drug monitoring for clinical laboratories. Antimicrob Agents Chemother 2013; 57:3437-40. [PMID: 23650161 DOI: 10.1128/aac.00323-13] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
We describe here a simple, fast, and reliable bioassay method for therapeutic drug monitoring of voriconazole. Fifty-eight clinical and external quality control samples were evaluated with this microbiological assay, and results were compared with those obtained with a previously validated chromatographic method. A good correlation between both assays was observed. This particular microbiological method was demonstrated to be simple and offers enough precision and accuracy to perform voriconazole therapeutic drug monitoring in laboratories without specialized equipment.
Collapse
|